TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05013151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dates
Description: Consumption of 6 dates a days until 41 weeks of gestation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Castor oil
Description: One time consumption of 60 CC Castor oil
Study: NCT05907213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar) Dose Level 1
Description: Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar) Dose Level 2
Description: Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar) Dose Level 3
Description: Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar) Dose Level 4
Description: Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
Study: NCT06425081

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Limosilactobacillus reuteri AMBV339
Description: Limosilactobacillus reuteri AMBV339 is a probiotic strain

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Humiome B2
Description: Colon-delivered Riboflavin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Limosilactobacillus reuteri AMBV339 + Humiome B2
Description: Combination of supplements used in arm 1 and 2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study: NCT06493032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Alimetry System
Description: medical device that uses a large sheet of electrodes to assess gastric motility
Study: NCT05067595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo lower FMT via colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo lower FMT via colonoscopy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Given upper FMT PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Given upper FMT PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo lower FMT via colonoscopy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo lower FMT via colonoscopy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given dietary fiber supplementation PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given dietary fiber supplementation PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue, stool, stool swabs, and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue, stool, stool swabs, and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue, stool, stool swabs, and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue, stool, stool swabs, and blood sample collection
Study: NCT06138249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D
Study: NCT05485363

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonographic measurement of the optic nerve sheath diameter
Description: Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
Study: NCT06523569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM) system
Description: As a part of the bundled digital health intervention, the participant will be given a Bluetooth-enabled remote patient monitoring system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application
Description: As a part of the bundled digital health intervention, the participant will be given a lifestyle change mobile health application.
Study: NCT06242535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLY-LOW
Description: The supplement, GLY-LOW, is FDA approved for use as a dietary supplement (IND 162006)
Study: NCT05764616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PARASTERNAL BLOCK
Description: After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PARASTERNAL BLOCK
Description: After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOCAL INFILTRATION OF DRAINAGE EXIT SITES
Description: At the end of surgery, a local infiltration of drainage exit sites will be performed with 10 mL of ropivacaine 0.25% per side

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RECTUS SHEATH BLOCK
Description: At the end of surgery, a rectus sheath block will be performed with 10 mL of ropivacaine 0.25% per side.
Study: NCT04166344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happyair Ecosystem
Description: Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online \& offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects.
Study: NCT03962244

Intervention type: DEVICE
Intervention: EsoSponge
Description: Endoscopically placed an EsoSponge for Negative pressure wound therapy in the area of the esophagogastric anastomotic leaks

Intervention type: DEVICE
Intervention: Self-Expanding Metal Stent
Description: Endoscopically placed self-expanding-metal-stent (SEMS) for negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
Study: NCT05912140

Intervention type: OTHER
Intervention: TRACE 2
Description: The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4).
Study: NCT04745949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT05127148

Intervention type: OTHER
Intervention: Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
Description: Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.
Study: NCT05809713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-enabled Team Care
Description: Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
Study: NCT06066996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Blinded Nicotine Patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nicotine Patch
Description: Blinded Patch with No Nicotine
Study: NCT06078774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Health Coach
Description: Dyads first session will be 60-minutes, totaling 1 hour. Dyads will participate in weekly 30-minute sessions for weeks 2-12, totaling 5.5 hours.~Dyads will participate bi-weekly 30-minute sessions for 12 weeks, totaling 3 hours.~Dyads will participate in weekly 30-minute exercise sessions for 24-weeks, totaling 12 hours.~Children will have 3, 30-minute visits with their primary care physician (PCP) every 3 months, totaling 1.5 hours.~Parents will have three, 60-minute individual sessions, totaling 3 hours. Total study duration is 24 weeks, with a total of 26 contact hours.~Sessions follow a behavior therapy approach, including guided goal-setting, self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks, maintenance and relapse prevention. Weight is assessed weekly by coaches, with MI-consistent, autonomy-supportive feedback provided. Parent sessions will focus on ways to support their child's weight management.
Study: NCT05615363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 10mg group
Description: OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 5mg group
Description: OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 2mg group
Description: OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC 131461 1mg group
Description: OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
Study: NCT05994391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LasoperinTM
Description: Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin
Study: NCT05615363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet，once-daily oral administration for 14 days
Study: NCT05508035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan
Description: The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
Study: NCT05994391

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placeo
Description: Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose
Study: NCT05508035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
Study: NCT05173831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Initial dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manualized therapy performed by therapist team
Study: NCT05542225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
Study: NCT04723888

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-ketoglutarate
Description: alpha-ketoglutarate supplements
Study: NCT05209776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral immunological assessment on venous blood
Description: Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral immunological assessment on venous blood
Description: Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
Study: NCT05469867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorNeat EverPatch
Description: The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
Study: NCT05209776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunological assessment carried out on intracardiac material
Description: Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
Study: NCT05044065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress (blood flow restriction exercise) during both a pre- and postoperative period consisting of a total of 6-10 weeks. Protein supplementation will be given to exclude insufficient intake.
Study: NCT04545983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motion Analysis
Description: Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Analysis
Description: Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
Study: NCT05738070

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
Study: NCT05326633

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)
Description: Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
Study: NCT04391218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Approach Group
Description: Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
Study: NCT05204771

Intervention type: OTHER
Intervention: Ultrasound exam
Description: Ultrasound exam

Intervention type: OTHER
Intervention: Postnatal abdominal ultrasound
Description: Postnatal abdominal ultrasound

Intervention type: OTHER
Intervention: Pediatric Follow up
Description: Pediatric Follow up
Study: NCT05239403

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05202353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide